Literature DB >> 10924361

Phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by protein kinase N.

T Hamaguchi1, M Ito, J Feng, T Seko, M Koyama, H Machida, K Takase, M Amano, K Kaibuchi, D J Hartshorne, T Nakano.   

Abstract

CPI-17 is a phosphorylation-dependent inhibitory protein for smooth muscle myosin phosphate. Phosphorylation at Thr(38), in vitro, by protein kinase C or Rho-kinase enhances the inhibitory potency toward myosin phosphatase. Phosphorylation of CPI-17 by protein kinase N (PKN), a fatty acid- and Rho-activated serine/threonine kinase, and its effect on smooth muscle myosin phosphatase activity were investigated. CPI-17 was phosphorylated by GST-PKN-CAT, a constitutively active GST-fusion fragment of PKN, to 1.46 mol of P/mol of CPI-17, in vitro. The K(m) value of CPI-17 for PKN was 0.96 microM. Phosphorylation of PKN dramatically increased the inhibitory effect of CPI-17 on myosin phosphatase activity. The major and inhibitory phosphorylation site was identified as Thr(38) using a point mutant of CPI-17 and a phosphorylation-state specific antibody. Thus, CPI-17 is a substrate of PKN and might be involved in the Ca(2+) sensitization of smooth muscle contraction as a downstream effector of Rho and/or arachidonic acid. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924361     DOI: 10.1006/bbrc.2000.3225

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Expression of CPI-17 and myosin phosphatase correlates with Ca(2+) sensitivity of protein kinase C-induced contraction in rabbit smooth muscle.

Authors:  T P Woodsome; M Eto; A Everett; D L Brautigan; T Kitazawa
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

Review 2.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

3.  PKN-1, a homologue of mammalian PKN, is involved in the regulation of muscle contraction and force transmission in C. elegans.

Authors:  Hiroshi Qadota; Takayuki Miyauchi; John F Nahabedian; Jeffrey N Stirman; Hang Lu; Mutsuki Amano; Guy M Benian; Kozo Kaibuchi
Journal:  J Mol Biol       Date:  2011-01-26       Impact factor: 5.469

Review 4.  Protein kinase network in the regulation of phosphorylation and dephosphorylation of smooth muscle myosin light chain.

Authors:  Katusya Hirano; Dmitry N Derkach; Mayumi Hirano; Junji Nishimura; Hideo Kanaide
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

5.  A novel RhoA/ROCK-CPI-17-MEF2C signaling pathway regulates vascular smooth muscle cell gene expression.

Authors:  Christina Pagiatakis; Joseph W Gordon; Saviz Ehyai; John C McDermott
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 6.  Regulation of the uterine contractile apparatus and cytoskeleton.

Authors:  Michael J Taggart; Kathleen G Morgan
Journal:  Semin Cell Dev Biol       Date:  2007-05-18       Impact factor: 7.727

Review 7.  Intestinal dysmotility in inflammatory bowel disease: mechanisms of the reduced activity of smooth muscle contraction.

Authors:  Hiroshi Ozaki; Masatoshi Hori; Kazuya Kinoshita; Takashi Ohama
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

8.  GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA.

Authors:  Qing-Rong Liu; Ping-Wu Zhang; Zhicheng Lin; Qi-Fu Li; Amina S Woods; Juan Troncoso; George R Uhl
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

9.  Little ROCK is a ROCK1 pseudogene expressed in human smooth muscle cells.

Authors:  Maria Claudia Montefusco; Kristen Merlo; Crystal D Bryan; Howard K Surks; Steven E Reis; Michael E Mendelsohn; Gordon S Huggins
Journal:  BMC Genet       Date:  2010-04-14       Impact factor: 2.797

10.  Phosphorylation of the myosin phosphatase inhibitors, CPI-17 and PHI-1, by integrin-linked kinase.

Authors:  Jing Ti Deng; Cindy Sutherland; David L Brautigan; Masumi Eto; Michael P Walsh
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.